Tirzepatide in Denver: How It Works and How It Compares to Semaglutide

Tirzepatide acts on two gut hormone receptors. Semaglutide acts on one. In the only head-to-head trial comparing them for weight loss, tirzepatide produced more weight loss, and that still does not automatically make it the right medication for you.

If you have been researching weight loss medication in Denver, you probably met semaglutide first. Tirzepatide is the newer molecule in the same conversation.

What is tirzepatide, and how is it different from semaglutide?

Both medications copy hormones your gut releases after you eat. Semaglutide is a GLP-1 receptor agonist: it mimics one of them. Tirzepatide is a dual GIP and GLP-1 receptor agonist, one molecule that activates the receptors for two: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1.

Picture a dimmer switch on appetite. Semaglutide turns one dimmer down. Tirzepatide reaches for two dimmers in the same room. Both GIP and GLP-1 receptors sit in areas of the brain involved in appetite regulation, and tirzepatide lowers how many calories you take in, likely by changing appetite.

That second receptor is why researchers expected a difference. It is not proof of one.

The brand names cause real confusion. Tirzepatide is sold under two of them. Zepbound is FDA-approved, along with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or adults with overweight plus at least one weight-related condition. Since December 20, 2024 it is also approved for moderate to severe obstructive sleep apnea in adults with obesity. It is not approved for type 2 diabetes. Mounjaro is the same molecule approved for a different job: blood sugar control in adults and children 10 and older with type 2 diabetes, not weight loss.

Semaglutide splits the same way. Wegovy is FDA-approved for weight in adults and children 12 and older with obesity, and in adults with overweight plus at least one weight-related condition. Ozempic is approved for type 2 diabetes in adults, not for weight loss. We walk through that split, and what "food noise" feels like, in our semaglutide guide.

Tirzepatide vs semaglutide: what does the research show?

One randomized trial has compared them directly for obesity. SURMOUNT-5 enrolled 751 adults with obesity, or overweight plus a weight-related condition, who did not have type 2 diabetes, then assigned them at random to tirzepatide or semaglutide at the highest tolerated dose for 72 weeks.

Average weight change at 72 weeks was 20.2 percent with tirzepatide and 13.7 percent with semaglutide. In pounds, that averaged 50.3 against 33.1. About 65 percent of the tirzepatide group lost at least 15 percent of their body weight, compared with 40 percent of the semaglutide group.

It was open-label, so participants and staff knew which medication they were getting, and it was funded by Eli Lilly, which makes tirzepatide. Neither fact makes the result wrong.

Real-world data points the same direction. A 2026 analysis in PNAS Nexus matched 10,339 patients on each medication and found mean maximum weight reduction over two years of 14.7 percent with tirzepatide and 10.8 percent with semaglutide. A 2024 study in JAMA Internal Medicine, covering 18,386 matched adults taking the diabetes-labeled versions, found tirzepatide patients roughly three times as likely to reach 15 percent loss. It also found that more than half of the patients in both groups stopped their medication during follow-up.

The direction is consistent across the trial and the real-world data.

Where does semaglutide still have the edge?

Semaglutide has outcome evidence that tirzepatide does not have yet.

The SELECT trial followed 17,604 adults with existing cardiovascular disease and a BMI of 27 or higher, without diabetes. Semaglutide 2.4 mg weekly lowered the combined rate of cardiovascular death, non-fatal heart attack, and non-fatal stroke to 6.5 percent, against 8.0 percent on placebo, over about 40 months. That is why Wegovy earned an FDA indication in March 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults with known heart disease and either obesity or overweight. In that same trial, 16.6 percent on semaglutide stopped because of side effects, against 8.2 percent on placebo.

Tirzepatide has no equivalent result. Its cardiovascular outcomes trial compared it against another GLP-1 medication rather than a placebo, in adults with type 2 diabetes, and found it about as good as that comparison drug, not better, on the main heart endpoint. The placebo-controlled study in people with obesity is still running, with completion estimated in October 2027. As of August 2026, no completed placebo-controlled trial shows that tirzepatide prevents heart attacks or strokes in people who have obesity without diabetes.

A provider may steer you toward semaglutide for other reasons too. Wegovy is approved down to age 12 for obesity, while Zepbound is adults only. Wegovy also carries an accelerated approval from August 2025, a conditional approval that has to be confirmed by further research, for a fatty liver disease called MASH, at the moderate to advanced scarring stage, in adults. There is a Wegovy tablet too, approved for weight and for heart risk in adults. Tirzepatide has neither.

What are the side effects of tirzepatide?

Both medications carry an FDA boxed warning about thyroid C-cell tumors seen in rodents. Whether that risk carries over to humans has not been determined. Both are off the table if you or a close relative has had medullary thyroid carcinoma, or if you have Multiple Endocrine Neoplasia syndrome type 2. That is a contraindication on the label, not a judgment call, and it is one of the first things we ask about.

The everyday side effects are mostly digestive. In the trials behind the Zepbound label, nausea affected 25 to 29 percent of patients depending on dose, against 8 percent on placebo. Diarrhea ran 19 to 23 percent against 8 percent, vomiting 8 to 13 percent against 2 percent, and constipation 11 to 17 percent against 5 percent. Between 4.8 and 6.7 percent of patients stopped because of side effects, against 3.4 percent on placebo, and most who stopped did so in the first few months. If the first weeks feel rough, tell us early rather than pushing through on your own. That is the part we plan for.

The label also warns about severe gastrointestinal reactions, kidney injury from dehydration, gallbladder problems, pancreatitis, serious allergic reactions, and low blood sugar if you take insulin or a sulfonylurea, an older type of diabetes pill. Tell any provider before surgery or sedation, because these medications slow stomach emptying and raise the risk of stomach contents getting into the lungs during anesthesia. If you take an oral contraceptive, use a backup method for four weeks after you start and after each dose increase.

Which of the two is gentler on the stomach is not settled. SURMOUNT-5 favored tirzepatide numerically, but it was not designed to answer that question, and the JAMA Internal Medicine study found similar rates between them. We do not tell patients one is easier. We watch how you do on the one you start.

What does a medically supervised tirzepatide program look like in Denver?

Tirzepatide is a once-weekly injection you give yourself, any time of day, with or without food, rotating between the abdomen, thigh, and back of the upper arm. You start at 2.5 mg for four weeks, a starting dose rather than a maintenance dose, then step up 2.5 mg at a time with at least four weeks between increases. Maintenance for weight is 5, 10, or 15 mg weekly, and 15 mg is the ceiling. The slow ladder blunts the nausea.

What to expect at Redbud

At Redbud, our boutique med spa in Denver, this starts with a conversation, not a form. Your provider reviews your personal and family history, your medications, what you have already tried, and whether this class fits you at all. Some people are not candidates, and we say so. If you do start, you get scheduled check-ins, dose adjustments based on how you are doing rather than a fixed calendar, and a plan for protein, movement, and what happens when you reach your goal. We walk through cost openly at your consultation.

Read more about our tirzepatide program or compare it with semaglutide. General questions about candidacy are answered on our FAQ page.

So which one is right for you?

Tirzepatide produced more weight loss in the one trial that compared them head to head. Semaglutide has the heart-outcomes evidence and the wider set of approved uses. Your history, your other conditions, and how your body handles the medication all move the answer. That is a clinical decision, not a leaderboard. When you are ready to have it, book a consultation.

This article is for general education and is not medical advice. Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity, or adults with overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. It is not approved for type 2 diabetes or for children. Wegovy (semaglutide) is approved for chronic weight management in adults and children 12 and older with obesity, and in adults with overweight plus a weight-related condition. Mounjaro and Ozempic are approved for type 2 diabetes, not for weight loss. Both molecules carry a boxed warning regarding thyroid C-cell tumors seen in rodents. Results vary. Whether either is right for you is a decision to make with a licensed provider.

---